Skip to main content

Table 2 Monthly Cost Summary

From: Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

 

Costs in $ per montha

Perspective

Germany

United States

Item

Cabozantinib

BSC

Cabozantinib

BSC

Cabozantinib drug

6841

0

21,581

0

Consultation

37

37

110 (75)

110 (75)

Laboratory

27 (14)

27 (14)

110 (55)

110 (55)

Imaging

93

93

162

162

AE total

682 (139)

213 (52)

1673 (645)

557 (166)

Diarrhea

271 (13)

48 (4)

444 (24)

80 (8)

Hand-foot-syndrome

42 (29)

3 (2)

385 (315)

25 (20)

Fatigue

15

9

93

56

Nausea and vomiting

93 (45)

64 (26)

168 (77)

116 (44)

Hypertension

17 (12)

2

78 (70)

11

Abdominal pain

24 (0)

41 (0)

122 (0)

187 (0)

Stomatitis

4

1

7

1

Rash

16

8

52

27

Thrombocytopenia

32 (0)

0

78 (0)

0

Dyspepsia

2 (0)

1 (0)

8 (0)

2 (0)

Hypokalemia

88 (1)

24 (< 1)

121 (3)

33 (1)

Pain in extremity

2 (0)

1 (0)

1 (0)

< 1 (0)

Hypothyroidism

13 (< 1)

< 1

21 (3)

< 1

Hypomagnesemia

33 (0)

0

45 (0)

0

Urinary tract infection

26 (0)

11 (0)

45 (0)

19 (0)

  1. The listed AE costs are already incidence-weighted. AE adverse event, BSC best supportive care. a Deviating costs of second and following months in brackets